查看基于多柔比星的化疗对右心房肿块和心包积液狗的回顾性评估的源代码
←
基于多柔比星的化疗对右心房肿块和心包积液狗的回顾性评估
跳转到:
导航
,
搜索
因为以下原因,你没有权限编辑本页:
您刚才请求的操作只有这个用户组中的用户才能使用:
用户
您可以查看并复制此页面的源代码:
== Results == 16只狗符合该研究的纳入标准。代表的品种包括金毛猎犬(n = 4)、杂交品种(n = 2)和以下品种各一只狗:挪威麋鹿猎犬、罗威纳犬、拳击手、比格犬、德国短毛指针犬、澳大利亚牧羊犬、西伯利亚雪橇犬、澳大利亚牧牛犬、莱昂伯格犬和红色法老猎犬。信号、主诉和体格检查结果见表 1-3。 Sixteen dogs met the inclusion criteria for the study. Breeds represented included golden retriever (n = 4), crossbreed (n = 2) and one dog each of the following breeds: Norwegian elkhound, Rottweiler, boxer, beagle, German shorthaired pointer, Australian shepherd, Siberian husky, Australian cattle dog, Leonberger and red Pharaoh hound. Signalment, presenting complaints and physical examination findings are shown in Tables 1-3. [[文件:Doxorubicin.RA.mass.PE.Table1-4.png]] 对所有 16 只狗进行了胸片检查,对 14 只狗进行了心电图检查,对 12 只狗进行了腹部超声检查。胸片、心电图和腹部超声检查发现的异常频率见表 4。八只狗的心脏肿块来自右心房,四只狗的 RA 附属物和四只狗的右房室沟。中位质量大小为 2.8 厘米 × 3.8 厘米(范围 1.8 厘米×2.2 厘米至 6.97 厘米×4.86 厘米)。提交了 14 只狗的 PE 样本进行分析,所有 14 只狗的出血性积液一致。在接受化疗的 16 只狗中,10 只狗接受多柔比星和环磷酰胺,4 只狗单独接受多柔比星,1 只狗接受多柔比星和异环磷酰胺,最后一只狗接受多柔比星和达卡巴嗪。化疗的副作用很常见,但通常被描述为轻度和自限性。 Thoracic radiographs were performed in all 16 dogs, while electrocardiography was performed in 14 dogs and abdominal ultrasonography was performed in 12 dogs. The frequency of abnormalities identified on thoracic radiographs, electrocardiography and abdominal ultrasound is shown in Table 4. The cardiac mass was identified originating from the right atrium in eight dogs, RA appendage in four dogs and in the right AV groove in four dogs. The median mass size was 2 · 8 cm×3 · 8 cm (range 1 · 8 cm×2 · 2 cm to 6 · 97 cm×4 · 86 cm). A sample of PE was submitted for analysis in 14 dogs and was consistent with a haemorrhagic effusion in all 14 dogs. Of the 16 dogs that received chemotherapy, 10 dogs received doxorubicin with cyclophosphamide, 4 dogs received doxorubicin alone, 1 dog received doxorubicin and ifosfamide and the last dog received doxorubicin and dacarbazine. Side effects attributed to chemotherapy were common but were typically described as mild and self-limiting. [[文件:Doxorubicin.RA.mass.PE.Fig1.png]] 在研究期结束时,所有狗都已死亡。死因是复发性肺栓塞 (n = 4)、未记录 (n = 3)、腹腔出血 (n = 2)、安乐死、未记录原因 (n = 2) 和以下各一项:在家中猝死、心包穿刺时心室颤动、血胸、肺炎和急性神经系统症状,包括癫痫发作伴前庭体征。一只狗在尸检中被组织学证实患有 RA HSA,并且是病例系列中所有狗中存活时间最长的狗之一(298 天)。接受基于多柔比星的化疗的狗的中位生存时间为 139.5 天(范围 2 至 302 天)(图 1)。 All dogs had died by the conclusion of the study period. Cause of death was recurrent PE (n = 4), not recorded (n = 3), haemoabdomen (n = 2), euthanasia, cause not recorded (n = 2) and one each of the following: sudden death at home, ventricular fibrillation during pericardiocentesis, haemothorax, pneumonia, and acute neurological symptoms consisting of seizures with vestibular signs. One dog was histologically confirmed to have a RA HSA on post-mortem examination and had one of the longest survival times of all dogs in the case series (298 days). Dogs that received doxorubicin-based chemotherapy had a median survival time of 139 · 5 days (range 2 to 302 days) (Fig 1). <br>
返回到
基于多柔比星的化疗对右心房肿块和心包积液狗的回顾性评估
。
个人工具
登录
名字空间
页面
讨论
变换
查看
阅读
查看源代码
查看历史
操作
搜索
导航
首页
社区专页
新闻动态
最近更改
随机页面
帮助
工具箱
链入页面
相关更改
特殊页面